252 related articles for article (PubMed ID: 30824167)
1. Design, synthesis and biological evaluation of pyridone-aminal derivatives as MNK1/2 inhibitors.
Yuan X; Wu H; Bu H; Zheng P; Zhou J; Zhang H
Bioorg Med Chem; 2019 Apr; 27(7):1211-1225. PubMed ID: 30824167
[TBL] [Abstract][Full Text] [Related]
2. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of 4-(indolin-1-yl)-6-substituted-pyrido[3,2-d]pyrimidine derivatives as Mnk1/2 inhibitors.
Xing K; Zhang H; Wang S; Li J; Mu Z; Zhang L; Zuo S; Wang Y; Li S; Wu B; Jing Y; Wen J; Liu D; Huang M; Zhao L
Eur J Med Chem; 2024 Jun; 272():116499. PubMed ID: 38759457
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
Zhang M; Jiang L; Tao J; Pan Z; He M; Su D; He G; Jiang Q
Bioorg Med Chem; 2019 Jun; 27(11):2268-2279. PubMed ID: 31014565
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of imidazopyridazine derivatives containing isoquinoline group as potent MNK1/2 inhibitors.
Bu H; Yuan X; Wu H; Zhou J; Zhang H
Bioorg Med Chem; 2021 Jun; 40():116186. PubMed ID: 33971490
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel 6-hydroxy-4-methoxy-3-methylbenzofuran-7-carboxamide derivatives as potent Mnks inhibitors by fragment-based drug design.
Wang S; Li B; Liu B; Huang M; Li D; Guan L; Zang J; Liu D; Zhao L
Bioorg Med Chem; 2018 Sep; 26(16):4602-4614. PubMed ID: 30115493
[TBL] [Abstract][Full Text] [Related]
7. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
[TBL] [Abstract][Full Text] [Related]
8. Discovery of indazole-pyridinone derivatives as a novel class of potent and selective MNK1/2 kinase inhibitors that protecting against endotoxin-induced septic shock.
Dreas A; Kucwaj-Brysz K; Pyziak K; Kulesza U; Wincza E; Fabritius CH; Michalik K; Gabor-Worwa E; Gołas A; Milik M; Masiejczyk M; Majewska E; Pyśniak K; Wójcik-Trechcińska U; Sandowska-Markiewicz Z; Brzózka K; Ostrowski J; Rzymski T; Mikula M
Eur J Med Chem; 2021 Mar; 213():113057. PubMed ID: 33303237
[TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors.
Abdelaziz AM; Basnet SKC; Islam S; Li M; Tadesse S; Albrecht H; Gerber C; Yu M; Wang S
Bioorg Med Chem Lett; 2019 Sep; 29(18):2650-2654. PubMed ID: 31362920
[TBL] [Abstract][Full Text] [Related]
11. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.
Ueda T; Watanabe-Fukunaga R; Fukuyama H; Nagata S; Fukunaga R
Mol Cell Biol; 2004 Aug; 24(15):6539-49. PubMed ID: 15254222
[TBL] [Abstract][Full Text] [Related]
12. Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.
Kwiatkowski J; Liu B; Pang S; Ahmad NHB; Wang G; Poulsen A; Yang H; Poh YR; Tee DHY; Ong E; Retna P; Dinie N; Kwek P; Wee JLK; Manoharan V; Low CB; Seah PG; Pendharkar V; Sangthongpitag K; Joy J; Baburajendran N; Jansson AE; Nacro K; Hill J; Keller TH; Hung AW
J Med Chem; 2020 Jan; 63(2):621-637. PubMed ID: 31910010
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.
Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S
ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692
[TBL] [Abstract][Full Text] [Related]
14. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
15. BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity.
Santag S; Siegel F; Wengner AM; Lange C; Bömer U; Eis K; Pühler F; Lienau P; Bergemann L; Michels M; von Nussbaum F; Mumberg D; Petersen K
Cancer Lett; 2017 Apr; 390():21-29. PubMed ID: 28043914
[TBL] [Abstract][Full Text] [Related]
16. Probing the binding mechanism of Mnk inhibitors by docking and molecular dynamics simulations.
Kannan S; Poulsen A; Yang HY; Ho M; Ang SH; Eldwin TS; Jeyaraj DA; Chennamaneni LR; Liu B; Hill J; Verma CS; Nacro K
Biochemistry; 2015 Jan; 54(1):32-46. PubMed ID: 25431995
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2.
Basnet SK; Diab S; Schmid R; Yu M; Yang Y; Gillam TA; Teo T; Li P; Peat T; Albrecht H; Wang S
Mol Pharmacol; 2015 Nov; 88(5):935-48. PubMed ID: 26268528
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
[TBL] [Abstract][Full Text] [Related]
19. Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.
Diab S; Abdelaziz AM; Li P; Teo T; Basnet SKC; Noll B; Rahaman MH; Lu J; Hou J; Yu M; Le BT; Albrecht H; Milne RW; Wang S
Eur J Med Chem; 2017 Oct; 139():762-772. PubMed ID: 28863357
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
